TAK-881
TAK-881-3003
Phase 3 mab active
Quick answer
TAK-881 for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Phase
- Phase 3
- Modality
- mab
- Status
- active